Shop Crisanta LS tablet Generic drug Drospirenone and Ethinyl Estradiol of online at a low price from most trusted pharmacy to cure Contraception. Get all info about this medicine like the review, use, side effect, dosage (missed/over), how long does the last Composition, Substitutes, manufactured by Cipla Pharmaceutical Industries Ltd, how it works, Precautions and many more. You can also get speedy delivery in the UK, USA, Australia, France, China.

This medicine is used for Contraception; this medication is the composition of 0.03 mg of ethinyl estradiol and 3 mg of drospirenone as active ingredients.which which helps in the prevention of pregnancy. This Tablet manufactured by Cipla Pharmaceutical Industries Ltd.

This tablet is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive.

The mechanism(work) of this interaction appears to be based on the hepatic enzyme-including properties of these active substances. Maximal enzyme induction usually is not seen for 2-3 weeks but may then be sustained for at least four weeks after the cessation of drug therapy.

Combined oral contraceptives containing ethinyl estradiol may inhibit the metabolism of other compounds. Increased plasma concentrations of prednisolone, theophylline, and cyclosporine have been reported with concomitant administration of oral contraceptives.

Decrease plasma concentrations of acetaminophen and increased clearance of temazepam, morphine,clofibric acid, and salicylic acid have been noted when these drugs were provided with contraceptives(pregnancy).

Day 1 start

During the first cycle of this drug use, the patient should be instructed to take one tablet daily, beginning on Day one of her menstrual cycle.

It is recommended that this drug is taken at the same time each day, preferably after the evening meal or at bedtime.

If this medicine is first taken later than the first day of the menstrual cycle, this medication should not be considered effective as a contraceptive until after the early seven consecutive days of product administration.

Cipladay start

During the first cycle of this pill use, the patient should be instructed to take one pill of Crisanta LS Tablet daily, beginning on the first Cipladay after the onset of her menstrual period.

The sufferer should begin her next and all subsequent 21 days regimens of this medicine on the same day of the week that ladies began her first regimen, next to the same timetable.

Anytime a subsequent cycle of this medication is started later than last treatment free day of her previous period; the patient should use another method of contraception until she has taken this tablet daily for seven consecutive days.

When switching from another oral contraceptive, this drug should be started on the same day that a new pack of the next oral contraceptive would have been started.

Withdrawal bleeding usually occurs within three days following the last tablet. If spotting/ breakthrough bleeding occurs while taking this pill, the patient should be instructed to continue taking her medication as taught and by the regimen described above.

She should be told that this type of bleeding is usually transient and without significance; but, if the bleeding is prolonged, the sufferer should be advised to consult her physician.

while the occurrence of pregnancy is low if this medicine is taken according to directions, if withdrawal bleeding does not occur, the chance of pregnancy must be considered.

On the off chance that the patient has not clung to the recommended dosing plan, the likelihood of pregnancy ought to be considered at the season of the primary missed period, and suitable indicative measures are taken.

If the sufferer has adhered to the prescribed regimen and misses two consecutive periods, pregnancy should be ruled out. The hormonal contraceptives should be discontinued if pregnancy is confirmed.

The possibility of pregnancy increases with each tablet of Crisanta LS Tablet being missed. If breakthrough bleeding occurs following missed pills, it will usually be transient and of no consequence.

To achieve maximum contraceptive effectiveness, this pill must be taken exactly as directed at intervals not exceeding 24 hours.

This medicine consists of 21 drugs of combined hormonal preparation. The dosage of Crisanta LS Tablet prescription is one pill daily for 21 consecutive days followed by seven treatment-free days per menstrual cycle.

A patient should begin to take this drug either on the first day of her menstrual period/the first Cipladay after the onset of her menstrual period.

Missed Dose

In case you miss a dose, use it as soon as you notice. If it is near to the time of your next dose, skip this dose and resume your dosing schedule. Do not use an extra dose to make up for a missed dose.

OverDose

Severe ill effects have not been reported following acute ingestion of large doses of other oral contraceptives by young children. Overdosage may cause nausea, vomiting, and withdrawal bleeding may occur in females.

Drospirenone, however, is a spironolactone analog which has anti mineralocorticoid properties. Serum concentration of sodium and potassium and evidence of metabolic acidosis should be monitored in cases of overdose. There are no antidotes, and further treatment should be symptomatic.

As per expert reviews, there are some side-effects associated with the use of this drug which is as follows.

Minor side effect

there are minor side-effects associated with the use of this medicine.

• Breast pain and tenderness
• Vomiting
• Weight gain
• Dizziness
• Depression
• Back pain
• A headache
• Vaginal discharge with no odor
• Flu-like symptoms

Major side effect

there are some significant side-effects associated with the use of this medication.

• Swelling of face, tongue, hands, lips, feet, and eyelids
• Troubled breathing and swallowing
• Change in the texture of nipples and breast skin
• Inverted nipples
• Breast pain
• Irregular uterine bleeding

General Instructions/warnings:

Crisanta LS Tablet drug contains 3 mg of the progestin drospirenone that has anti mineralocorticoid activity, including the potential for hyperkalemia in the high-risk sufferer, comparable to a 25 mg dose of spironolactone. Fixed dose combination of drospirenone and ethinyl estradiol should not be used in patients with conditions that predispose to hyperkalemia.

Ladies getting day by day, long-haul treatment for constant conditions or sicknesses with meds that may expand serum potassium, ought to have their serum potassium level checked amid the main treatment cycle. Medications that may expand serum potassium incorporate ACE inhibitors, angiotensin || receptor rivals, potassium-saving diuretics, heparin, aldosterone adversaries, and NSAIDs.

The utilization of oral contraceptives is related with expanded dangers of a few dangerous conditions including dead myocardial tissue, thromboembolism, stroke, hepatic neoplasia, gallbladder ailment, and hypertension, even though the danger of severe bleakness or mortality is little in sound ladies without essential hazard factors.

Oral contraceptives may exacerbate the impacts of surely understood hazard factors, for example, hypertension, diabetes, hyperlipidemias, age, and weight and fundamentally increment the danger of horribleness and mortality within sight of these essential hazard factors.

Ladies with a past filled with melancholy ought to be precisely watched and the medication suspended if despondency repeats to an extreme degree.

When Not to Use

In the nonlactating mother, Crisanta LS Tablet medicine may be initiated four weeks postpartum, for contraception. When the pills are administered in the postpartum period, the increased risk of thromboembolic disease associated with the postpartum period must be considered.

Pediatric use:

Safety and efficacy of this medication have been established in women of reproductive age. Safety and efficacy are expended to be the same for postpubertal adolescents under the age of 16 and users 16 yrs and older. Utilized of this product before menarche is not indicated.

Hepatic impairment:

this medicine is contraindicated in patients with hepatic dysfunction.

Renal impairment:

this drug is contraindicated in patients with renal insufficiency.

Warnings for special population

Pregnancy & Lactation

The fixed dose combination of drospirenone and ethinyl estradiol is not indicated during pregnancy.

During clinical studies out of the fourteen pregnancies that occurred with FDC of drospirenone and ethinyl estradiol exposure in utero, one infant was born with esophageal atresia. A causal association with FDC of drospirenone and ethinyl estradiol is unknown.

Epidemiological studies have revealed no increased possibility of birth defects in ladies who have used oral contraceptives before pregnancy. It is suggested that for any patient who has missed two consecutive periods, pregnancy should be ruled out.

The organization of oral contraceptives to incite withdrawal draining ought not to be utilized as a test for pregnancy. Oral contraceptive should not be used during pregnancy to treat threatened or habitual abortion.

The little amount of oral preventative steroids have been recognized in the drain of nursing moms, and a couple of antagonistic consequences for the tyke have been accounted for, including jaundice and bosom development. Also, oral contraceptives given in the postpartum period may interfere with lactation by decreasing the quantity and quality of breast milk.

After oral administration of FDC of drospirenone and ethinyl estradiol, about 0.02% of the drospirenone dose was excreted into the mother milk of postpartum ladies within 24 hrs. This results in a daily dose of about three mcg drospirenone in an infant.

Contradiction

• Hypersensitivity to the active substances or any of the excipients of the formulation.
• Severe renal insufficiency or acute renal failure.
• Hepatic dysfunction
• Adrenal insufficiency
• Thrombophlebitis or thromboembolic disorders.
• A history of deep vein thrombophlebitis, pulmonary embolism or thromboembolic disorders.
• Cerebral vascular or coronary artery disease.
• Valvular heart disease with thrombogenic complications
• Severe hypertension
• Diabetes with vascular involvement
• Headaches with focal neurological symptoms or a migraine.
• Known or suspected carcinoma of the breast.
• Carcinoma of the endometrium/other known or suspected estrogen-dependent neoplasia.
• Undiagnosed abnormal genital bleeding.
• Liver tumor or active liver disease.
• Cholestatic jaundice of pregnancy/jaundice with prior pill use.
• Known or suspected pregnancy.
• Heavy smoking and over age 35.
• Hereditary/ acquired predisposition for venous or arterial thrombosis, such as APC -resistance, antithrombin-||| deficiency, protein S deficiency, hyperhomocysteinemia, and antiphospholipid antibodies.
• Arterial thrombosis presence or in history or prodromal conditions. The presence of severe or multiple risk factor for arterial thrombosis.
• Severe dyslipoproteinemia.

Interactions between other medicinal products and oral contraceptives may lead to breakthrough bleeding and contraceptive failure. This has been established with primidone, hydantoins, carbamazepine, barbiturates, and rifampicin; oxcarbazepine, topiramate, felbamate, ritonavir, griseofulvin, and the herbal remedy St.John’s Wort are also suspected.